The use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial

dc.creatorSilveira, Marcelo Augusto Duarte
dc.creatorSouza, Sergio Pinto de
dc.creatorGalvão, Erica Batista dos Santos
dc.creatorTeixeira, Maurício Brito
dc.creatorGomes, Marcel Miranda Dantas
dc.creatorDamiani, Lucas Petri
dc.creatorBahiense, Bruno Andrade
dc.creatorCabral, Julia Barros
dc.creatorOliveira, Cicero Wandson Luiz Macedo de
dc.creatorMascarenhas, Talita Rocha
dc.creatorPinheiro, Priscila Carvalho Guedes
dc.creatorAlves, Milena Souza
dc.creatorMelo, Rodrigo Morel Vieira de
dc.creatorBerretta, Andresa Aparecida
dc.creatorLeite, Flávia Mendes
dc.creatorNonaka, Carolina Kymie Vasques
dc.creatorSouza, Bruno Solano de Freitas
dc.creatorMendes, Ana Verena Almeida
dc.creatorGuarda, Suzete Farias da
dc.creatorPassos, Rogério da Hora
dc.date2022-05-10T11:57:21Z
dc.date2022-05-10T11:57:21Z
dc.date2022
dc.date.accessioned2023-09-26T22:32:30Z
dc.date.available2023-09-26T22:32:30Z
dc.identifierSILVEIRA, Marcelo Augusto Duarte et al. The use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial. Trials, n. 255, p. 1-7, 2022.
dc.identifier1745-6215
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/52597
dc.identifier10.1186/s13063-022-06176-1
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8880530
dc.descriptionD'Or Institute for Education and Research. A Fundação Maria Emília Pedreira Freire de Carvalho (FME).
dc.descriptionBackground: The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. Experimental evidence has already been obtained for use of the standardized extract of Brazilian green propolis (EPP-AF) against viral targets, and clinical rationality has been demonstrated for testing this extract as an adjunct to treatment in patients affected by COVID-19. The BeeCovid2 study aims to assess whether EPP-AF has an impact on the improvement of patients hospitalized with COVID-19 by reducing the length of hospital stay. Methods: BeeCovid2 is a randomized, double-blinded, placebo-controlled clinical study being conducted in Brazil to provide further evidence on the effectiveness of standardized green propolis extract as an adjunctive treatment for adults hospitalized with COVID-19. Hospitalized patients over 18 years of age with a confirmed diagnosis of COVID-19 and up to 14 days of symptoms were included. Patients under mechanical ventilation at randomization, pregnant women, cancer patients, transplanted or using immunosuppression, HIV patients, patients who used propolis in the last 30 days, bacterial or fungal infection at randomization, impossibility of using medication orally or enterally, and advanced chronic diseases (e.g., advanced heart failure, severe liver disease, and end-stage chronic kidney disease). Enrolled patients are randomized at a 1:1 ratio to receive placebo or standardized propolis extract (900 mg/day) for 10 days. The study treatments are administered in a double-blinded manner, and patients are followed for 28 days. The primary outcome is the difference in length of hospital stay in days between groups. Secondary outcomes include the need for mechanical ventilation, the rate of secondary infection, rate of acute kidney injury, the need for renal replacement therapy, the requirement for vasoactive drugs, the use of an intra-aortic balloon pump (IABP), and the use of extracorporeal membrane oxygenation (ECMO). Discussion: This trial is very useful and will provide more data on the effectiveness of using the standardized Brazilian green propolis extract as an adjunctive treatment in association with standard care in adults hospitalized with moderate to severe acute COVID-19.
dc.formatapplication/pdf
dc.languageeng
dc.publisherBMC
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectRandomized Controlled Trial
dc.subjectPropolis
dc.subjectAnti-Inflammatory Agents
dc.subjectCOVID-19
dc.subjectTeste controlado e aleatório
dc.subjectProtocolo
dc.subjectPrópolis
dc.subjectAgentes anti-inflamatórios
dc.subjectImunoregulação
dc.subjectACE2
dc.subjectbloqueador PAK1
dc.subjectTMPRSS2
dc.subjectCOVID-19
dc.subjectRandomized controlled trial
dc.subjectProtocol
dc.subjectPropolis
dc.subjectAnti-inflammatory agents
dc.subjectImmunoregulation
dc.subjectACE2
dc.subjectPAK1 blocker
dc.subjectTMPRSS2
dc.subjectbloqueador PAK1
dc.subjectCOVID-19
dc.subjectEnsayo controlado aleatorizado
dc.subjectProtocolo
dc.subjectPropóleos
dc.subjectAgentes antiinflamatorios
dc.subjectinmunorregulación
dc.subjectACE2
dc.subjectbloqueador PAK
dc.subjectTMPRSS2
dc.subjectCOVID-19
dc.subjectEssai contrôlé randomisé
dc.subjectProtocole
dc.subjectPropolis
dc.subjectAgents anti-inflammatoires
dc.subjectImmunorégulation
dc.subjectACE2
dc.subjectBloqueur PAK1
dc.subjectTMPRSS2
dc.subjectCOVID-19
dc.subjectEnsaio Clínico Controlado Aleatório
dc.subjectProtocolo de Ensaio Clínico
dc.subjectPrópole
dc.subjectAnti-Inflamatórios
dc.subjectEnzima de Conversão de Angiotensina 2
dc.titleThe use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial
dc.typeArticle


Este ítem pertenece a la siguiente institución